Skip to main content

Advertisement

SpringerLink
Log in

Top Pancreatic Tumor Articles from 2021 to Inform Your Cancer Patients

  • Pancreatic Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

More than 10,000 publications about pancreatic cancer were found on PubMed during the past year.

Methods

To best inform patients with pancreatic cancer, the obvious, frequent questions asked during patient counseling when dealing with resectable pancreatic cancer, borderline resectable pancreatic cancer, and unresectable pancreatic cancer were considered.

Results

The publications highlighted are comprehensive on the current management of neoadjuvant therapy for resectable pancreatic cancer, the addition of radiation to neoadjuvant therapy for borderline resectable pancreatic cancer, the utility of arterial resections in unresectable pancreatic cancer, and the role of minimally invasive approach to pancreatic cancer surgical therapy.

Conclusion

These articles are high yield and comprehensive review on key issues facing surgical oncologists who operate on pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Taken from Van Dam et al. meta-analysis of randomized trials

Fig. 3

Similar content being viewed by others

References

  1. van Dam JL, Janssen QP, Besselink MG, et al. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomised controlled trials. Eur J Cancer. 2022;160:140–9. https://doi.org/10.1016/j.ejca.2021.10.023.

    Article  CAS  PubMed  Google Scholar 

  2. Golcher H, Brunner TB, Witzigmann H, et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol. 2015;191(1):7–16. https://doi.org/10.1007/s00066-014-0737-7.

    Article  PubMed  Google Scholar 

  3. Casadei R, Di Marco M, Ricci C, et al. Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastrointest Surg. 2015;19(10):1802–12. https://doi.org/10.1007/s11605-015-2890-4.

    Article  PubMed  Google Scholar 

  4. Reni M, Balzano G, Zanon S, et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial. Lancet Gastroenterol Hepatol. 2018;3(6):413–23. https://doi.org/10.1016/S2468-1253(18)30081-5.

    Article  PubMed  Google Scholar 

  5. Jang JY, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268(2):215–22. https://doi.org/10.1097/SLA.0000000000002705.

    Article  PubMed  Google Scholar 

  6. Motoi F, Kosuge T, Ueno H, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol. 2019;49(2):190–4. https://doi.org/10.1093/jjco/hyy190.

    Article  PubMed  Google Scholar 

  7. Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763–73. https://doi.org/10.1200/JCO.19.02274.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ghaneh P, Palmer D, Cicconi S, et al. ESPAC-5F: four arm, prospective, multicentre, international randomised phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer. In: ASCO annual meeting. 2020. J Clin Oncol. 2020;38:4505. https://doi.org/10.1200/JCO.2020.38.15_suppl.4505

  9. Ahmad SA, Duong M, Sohal DPS, et al. Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX versus gemcitabine/nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma. Ann Surg. 2020;272(3):481–6. https://doi.org/10.1097/SLA.0000000000004155.

    Article  PubMed  Google Scholar 

  10. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–406. https://doi.org/10.1056/NEJMoa1809775.

    Article  CAS  PubMed  Google Scholar 

  11. Labori KJ, Lassen K, Hoem D, et al. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian pancreatic cancer trial-1 (NorPACT-1))—study protocol for a national multicentre randomized controlled trial. BMC Surg. 2017;17(1):94. https://doi.org/10.1186/s12893-017-0291-1.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Schwarz L, Vernerey D, Bachet JB, et al. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study) [published correction appears in BMC Cancer. 2020 Mar 3;20(1):168]. BMC Cancer. 2018;18(1):762. https://doi.org/10.1186/s12885-018-4663-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ferrone C. A Phase III Trial of perioperative versus adjuvant chemotherapy for resectable pancreatic cancer. ClinicalTrials.gov identifier: NCT04340141. Updated August 3, 2022. Accessed October 26, 2022. https://clinicaltrials.gov/ct2/show/NCT04340141.

  14. Koerkamp BG. Perioperative versus adjuvant FOLFIRINOX for resectable pancreatic cancer: the PREOPANC-3 Study. ClinicalTrials.gov identifier: NCT04927780. Updated June 21, 2022. Accessed October 26, 2022. https://www.clinicaltrials.gov/ct2/show/NCT04927780.

  15. Katz MHG, Shi Q, Meyers J, et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 Phase 2 randomized clinical trial. JAMA Oncol. 2022;8(9):1263–70. https://doi.org/10.1001/jamaoncol.2022.2319.

    Article  PubMed  Google Scholar 

  16. Hall WA, Dawson LA, Hong TS, et al. Value of neoadjuvant radiation therapy in the management of pancreatic adenocarcinoma. J Clin Oncol. 2021;39(34):3773–7. https://doi.org/10.1200/JCO.21.01220.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Janssen QP, van Dam JL, Prakash LR, et al. Neoadjuvant radiotherapy after (m)FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: a TAPS consortium study. J Natl Compr Canc Netw. 2022;20(7):783-91.e1. https://doi.org/10.6004/jnccn.2022.7008.

    Article  CAS  PubMed  Google Scholar 

  18. Conroy T. Two-arm, prospective, multicenter randomized phase II trial of neoadjuvant modified folfirinox regimen, with or without preoperative concomitant chemoradiotherapy in patients with borderline resectable pancreatic carcinoma. ClinicalTrials.gov identifier: NCT02676349. Updated March 31, 2022. Accessed October 26, 2022. https://clinicaltrials.gov/ct2/show/study/NCT02676349.

  19. Oar A. MASTERPLAN: A randomised phase II study of MFOLFIRINOX and stereotactic radiotherapy (SBRT) for pancreatic cancer with high risk and locally advanced disease. ClinicalTrials.gov identifier: NCT04089150. Updated October 22, 2021. Accessed October 26, 2022. https://www.clinicaltrials.gov/ct2/show/study/NCT04089150.

  20. Hall W. A randomized, phase II clinical trial of preoperative fractionated radiation therapy versus stereotactic body radiation therapy for resectable or borderline resectable, or locally advanced type A pancreatic adenocarcinoma. ClinicalTrials.gov identifier: NCT03704662. Updated July 20, 2022. Accessed October 26, 2022. https://www.clinicaltrials.gov/ct2/show/NCT03704662.

  21. Evans DB, George B, Tsai S. Nonmetastatic pancreatic cancer: resectable, borderline resectable, and locally advanced-definitions of increasing importance for the optimal delivery of multimodality therapy. Ann Surg Oncol. 2015;22(11):3409–13. https://doi.org/10.1245/s10434-015-4649-2.

    Article  PubMed  Google Scholar 

  22. Loos M, Kester T, Klaiber U, et al. Arterial resection in pancreatic cancer surgery: effective after a learning curve. Ann Surg. 2022;275(4):759–68. https://doi.org/10.1097/SLA.0000000000004054.

    Article  PubMed  Google Scholar 

  23. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003;349(22):2117–27. https://doi.org/10.1056/NEJMsa035205.

    Article  CAS  PubMed  Google Scholar 

  24. Moekotte AL, Rawashdeh A, Asbun HJ, et al. Safe implementation of minimally invasive pancreas resection: a systematic review. HPB (Oxford). 2020;22(5):637–48. https://doi.org/10.1016/j.hpb.2019.11.005.

    Article  PubMed  Google Scholar 

  25. van Hilst J, de Graaf N, Abu Hilal M, Besselink MG. The landmark series: minimally invasive pancreatic resection. Ann Surg Oncol. 2021;28(3):1447–56. https://doi.org/10.1245/s10434-020-09335-3.

    Article  PubMed  Google Scholar 

  26. van Hilst J, de Rooij T, Bosscha K, et al. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial. Lancet Gastroenterol Hepatol. 2019;4(3):199–207. https://doi.org/10.1016/S2468-1253(19)30004-4.

    Article  PubMed  Google Scholar 

  27. Zwart MJW, Nota CLM, de Rooij T, et al. Outcomes of a multicenter training program in robotic pancreatoduodenectomy (LAELAPS-3) [published online ahead of print, 2021 Feb 1]. Ann Surg. 2021. https://doi.org/10.1097/SLA.0000000000004783.

    Article  PubMed  Google Scholar 

  28. Wang M, Li D, Chen R, et al. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol. 2021;6(6):438–47. https://doi.org/10.1016/S2468-1253(21)00054-6.

    Article  PubMed  Google Scholar 

  29. Asbun HJ, Moekotte AL, Vissers FL, et al. The Miami International evidence-based guidelines on minimally invasive pancreas resection. Ann Surg. 2020;271(1):1–14. https://doi.org/10.1097/SLA.0000000000003590.

    Article  PubMed  Google Scholar 

  30. Korrel M, Lof S, Alseidi AA, et al. Framework for training in minimally invasive pancreatic surgery: an international Delphi consensus study. J Am Coll Surg. 2022;235(3):383–90. https://doi.org/10.1097/XCS.0000000000000278.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA

    Melissa E. Hogg MD, MS

  2. City of Hope, Duarte, CA, USA

    Laleh G. Melstrom MD, MSCI

Authors
  1. Melissa E. Hogg MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laleh G. Melstrom MD, MSCI
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Melissa E. Hogg MD, MS.

Ethics declarations

Disclosure

Melissa Hogg—Intuitive Surgical money to institution for training

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hogg, M.E., Melstrom, L.G. Top Pancreatic Tumor Articles from 2021 to Inform Your Cancer Patients. Ann Surg Oncol 30, 3437–3443 (2023). https://doi.org/10.1245/s10434-023-13277-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-023-13277-x

Search

Navigation